BCL2L12 and glioblastoma: Given that miR-182 has now been shown to target Bcl2L12, c-Met and HIF2A in GBM [5] and PPP1R1C, also in GBM, in this study, it would be interesting to evaluate HDAC inhibitors in GBM treatment.